Antibodies to Hnrnp B1 (RA33) in Patients with Systemic Sclerosis

Antibodies to Hnrnp B1 (RA33) in Patients with Systemic Sclerosis
Автор:  Maslyanskiy A. , Roggenbuck D. , Lapin S. , Mazing A. , Lazareva N., Ilivanova E., Kolesova E., Mazurov V.
Год:  2014
Файл:  Загрузить
Публикация: Annals of the Rheumatic Diseases 73(Suppl 2):867-867. June 2014


Background: Systemic sclerosis (SSc) is an autoimmune disease characterized by the occurrence of a wide range of autoantibodies (Aab) which can predictdistinct clinical features of SSc. Aab to hnRNP A2 and its alternatively spliced variants B1 (anti-hnRNP B1) and B2 are generally referred to as anti-RA33 and havebeen extensively studied in rheumatoid arthritis (RA) [1]. However, the prevalenceof anti-RA33 Aab in other autoimmune diseases, such as scleroderma, mixed connective tissue disease and systemic vasculitides, is far from determined [2–4].

Objectives: To compare the frequency of anti-hnRNP B1 with other SSc-specific Aab and to determine an association thereof with the clinical phenotype in patients with SSc.

Methods: We studied Aab prevalence in 64 patients with SSc, 29 with diffuse cutaneous SSc and 26 with limited cutaneous disease as well as 9 patients with overlap syndrome. Diagnosis of SSc in all patients was based on 1980 ACR (ARA) criteria and the disease phenotype was analyzed according to LeRoy’s classification criteria [7]. Serum samples from clinically healthy blood donors (n=174) were used as a control group. Skin involvement and disease severity was measured with Rodnan’s skin score and Valentini activity index. Vascular involvement was accessed by measurement of pulse wave velocity (PWV) and augmentation index (AI) with applanation tonometry (SphygmoCor system, AtCor Medical Pty Ltd., Sydney, Australia). Anti-hnRNP B1 IgG was assessed by an ELISA employing recombinant human hnRNP B1 expressed in E.coli (in.vent DIAGNOSTICA GmbH, Germany). SSc-specific Aab were measured with line immunoassay (Euroimmun AG, Germany) according to the manufacturer’s instructions.
Results: Anti-hnRNP B1 were found in 18.5% (12/64) of SSc patients and in 1.1% (2/174) of controls (p<0.001). Median concentrations were also significantly higher in SSc patients (p<0.001). There were no significant associations of anti-hnRNP B1 level with any other particular SSc-specific Aab, clinical form of the SSc, degree of skin involvement, and clinical activity. We found that anti-hnRNP B1 antibodies directly correlated with the presence (r=0.33 p=0.009) of arterial hypertension and vessel-wall stiffness parameters like PWV (r=0.39, p=0.004) and AI (r=0.35, p<0.001).

Maslyanskiy, Alexey & Roggenbuck, Dirk & Lapin, Sergey & Mazing, Alexandra & Lazareva, N. & Ilivanova, E. & Kolesova, Ekaterina & Mazurov, V.. (2014). AB0193 Antibodies to Hnrnp B1 (RA33) in Patients with Systemic Sclerosis. Annals of the Rheumatic Diseases. 73. 867-867. 10.1136/annrheumdis-2014-eular.2222.